Edwards Lifesciences (EW) Stock Forecast & Price Target

$81.70 +0.31 (+0.38%)

As of 02:56 PM Eastern

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
1

Hold
10

Buy
15

Based on 26 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 1 has given a sell rating, 10 have given a hold rating, 12 have given a buy rating, and 3 have given a strong buy rating for EW.

Consensus Price Target

$85.90
5.15% Upside

According to the 26 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $85.90. The highest price target for EW is $100.00, while the lowest price target for EW is $60.00. The average price target represents a forecasted upside of 5.15% from the current price of $81.70.

Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

EW Analyst Ratings Over Time

Type	Current Forecast 8/21/24 to 8/21/25	1 Month Ago 7/22/24 to 7/22/25	3 Months Ago 5/23/24 to 5/23/25	1 Year Ago 8/22/23 to 8/21/24
Strong Buy	3 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	11 Buy rating(s)	11 Buy rating(s)
Hold	10 Hold rating(s)	13 Hold rating(s)	12 Hold rating(s)	13 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$85.90	$81.00	$80.20	$82.10
Forecasted Upside	5.15% Upside	6.00% Upside	6.96% Upside	17.14% Upside
Consensus Rating	Moderate Buy	Hold	Hold	Moderate Buy

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Edwards Lifesciences Stock vs. The Competition

Type	Edwards Lifesciences	Medical Companies	S&P 500
Consensus Rating Score	2.65	2.79	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	4.46% Upside	13,730.66% Upside	11.82% Upside
News Sentiment Rating	Positive News See Recent EW News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/7/2025	Wells Fargo & Company 3 of 5 stars	Larry Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$84.00 ➝ $88.00	+13.49%
7/29/2025	Daiwa America 0 of 5 stars		Upgrade	Hold ➝ Strong-Buy
7/29/2025	BTIG Research 2 of 5 stars		Upgrade	Neutral ➝ Buy	$100.00	+27.45%
7/25/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
7/25/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Strong-Buy
7/25/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$80.00 ➝ $85.00	+6.36%
7/25/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$75.00 ➝ $81.00	+2.36%
7/25/2025	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$87.00 ➝ $95.00	+20.64%
7/25/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$81.00 ➝ $82.00	+2.31%
7/25/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$83.00 ➝ $90.00	+13.33%
Get the Latest News and Ratings for EW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter.
7/25/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$90.00 ➝ $95.00	+19.63%
7/25/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$90.00 ➝ $95.00	+19.63%
7/25/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$85.00 ➝ $89.00	+13.55%
7/25/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	In-Line ➝ In-Line	$77.00 ➝ $80.00	+0.28%
7/25/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Pito Chickering Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$85.00 ➝ $94.00	+24.21%
7/25/2025	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$78.00 ➝ $79.00	+4.39%
7/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$75.00 ➝ $81.00	+3.39%
7/10/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Dooley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/2/2025	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/22/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $95.00	+26.60%
2/12/2025	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
12/16/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$82.00 ➝ $90.00	+20.97%
10/28/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Hambright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/18/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$85.00 ➝ $70.00	+4.14%
9/12/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$90.00 ➝ $90.00	+34.71%
9/10/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$90.00 ➝ $75.00	+12.66%
7/31/2024	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform
7/25/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/25/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Jennings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$100.00 ➝ $70.00	+14.27%
3/26/2024	OTR Global Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Mixed ➝ Positive
10/16/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/16/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$75.00	+4.90%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:46 PM ET.

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 18, 2025. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

The current stock price is around $78, which is near its 52-week low of $64, potentially offering a buying opportunity for investors looking for value.
Recent quarterly earnings showed a strong performance with earnings per share of $0.67, exceeding analyst expectations, indicating robust financial health.
The company reported a revenue increase of 11.9% year-over-year, suggesting strong growth potential in its market segment.
Edwards Lifesciences Co. has a low debt-to-equity ratio of 0.06, indicating a strong balance sheet and lower financial risk, which is attractive for conservative investors.
The firm has a high net margin of 72.96%, reflecting efficient operations and profitability, which can lead to higher returns for shareholders.

Edwards Lifesciences
Bear Case

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

Insider selling has been observed, with significant shares sold recently, which may indicate a lack of confidence among company executives.
The stock has experienced a decrease in ownership by insiders, which could suggest potential concerns about the company's future performance.
Despite strong earnings, the stock's price-to-earnings ratio of 11.26 may not reflect future growth expectations, leading to potential overvaluation risks.
The company has a PEG ratio of 3.78, which indicates that the stock may be overvalued relative to its growth rate, making it less attractive for growth-focused investors.
Market volatility, as indicated by a beta of 1.08, suggests that the stock may be more sensitive to market fluctuations, posing risks for investors during uncertain times.

EW Forecast - Frequently Asked Questions

: According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $85.90, with a high forecast of $100.00 and a low forecast of $60.00.
: 26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There is currently 1 sell rating, 10 hold ratings, 12 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" EW shares.
: According to analysts, Edwards Lifesciences's stock has a predicted upside of 5.15% based on their 12-month stock forecasts.
: Over the previous 90 days, Edwards Lifesciences's stock had 5 upgrades by analysts.
: Edwards Lifesciences has been rated by research analysts at Argus, Barclays, BTIG Research, Canaccord Genuity Group, Daiwa America, Dbs Bank, Deutsche Bank Aktiengesellschaft, Evercore ISI, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, The Goldman Sachs Group, Truist Financial, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Edwards Lifesciences less than other "medical" companies. The consensus rating score for Edwards Lifesciences is 2.65 while the average consensus rating score for "medical" companies is 2.79. Learn more on how EW compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:EW) was last updated on 8/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edwards Lifesciences (EW) Stock Forecast & Price Target